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Abstract 
Increasing evidence suggests that the synaptic functions of the amyloid precursor protein 
(APP), that is key to Alzheimer pathogenesis, may be carried out by its secreted ectodomain. 
However, the specific role of APPs fragments generated by non-amyloidogenic or 
amyloidogenic APP processing remain unclear. Here, we expressed APPsα or APPs in the 
adult brain of conditional double knockout mice (cDKO) lacking APP and the related APLP2. 
APPsα efficiently rescued deficits in spine density, synaptic plasticity (LTP and PPF) and 
spatial reference memory of cDKO mice. In contrast, APPs failed to show any detectable 
effects on synaptic plasticity and spine density. The C-terminal 16 amino acids of APPsα 
(lacking in APPs) proved sufficient to facilitate LTP in a mechanism that depends on 
functional nicotinic 7-nAChRs. Further, APPs showed high-affinity, allosteric potentiation 
of heterologously expressed 7-nAChRs in oocytes. Collectively, we identified 7-nAChRs 
as a crucial physiological receptor specific for APPsα  and show distinct in vivo roles for 
APPsα versus APPsβ. This implies that reduced levels of APPsα that might occur during 
Alzheimer pathogenesis cannot be compensated by APPs. 
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Introduction 
Alzheimer’s disease (AD) is characterized by the accumulation of -amyloid peptides (A), 
that are derived from the amyloid precursor protein (APP) by proteolytic cleavage (Selkoe & 
Hardy, 2016). Two principal physiological pathways either prevent or promote A generation. 
Within the amyloidogenic pathway APP processing is shifted towards the production of A 
and secreted APPs, by consecutive -secretase (BACE1) and -secretase cleavage 
(Vassar et al, 2014). In AD BACE1 is upregulated, favoring amyloidogenic APP processing 
(Ahmed et al, 2010; Holsinger et al, 2002). In the alternative, non-amyloidogenic pathway 
cleavage of APP within the A region by the major -secretase ADAM10 (a disintegrin and 
metalloprotease) prevents A generation and liberates APPs, that is secreted into the 
extracellular space (Saftig & Lichtenthaler, 2015). Shifting APP processing towards non-
amyloidogenic processing has therefore been suggested as a therapeutic strategy for AD 
(Mockett et al, 2017). An important and still unresolved question is whether in addition to 
neurotoxic A accumulation a concomitant reduction in APPs level, or an altered 
APPs/APPs ratio may contribute to AD symptoms and pathogenesis (reviewed by Mockett 
et al, 2017). In this regard, it will be crucial to know whether APPs and APPs, that is only 
16 aminoacids shorter than APPs, serve largely similar or distinct, possibly even opposite 
physiological functions. While our previous studies and work from others indicated that 
APPs has neurotrophic and neuroprotective effects, including synaptogenic, LTP facilitating 
and memory enhancing properties (Hefter et al, 2016; Hick et al, 2015; Meziane et al, 1998; 
Milosch et al, 2014; Plummer et al, 2016; Ring et al, 2007; Taylor et al, 2008; Weyer et al, 
2014), only few and mostly conflicting studies have as yet addressed the functions of APPs 
(Chasseigneaux & Allinquant, 2012; Li et al, 2010; Nikolaev et al, 2009; Weyer et al, 2011). 
So far, the molecular basis of any difference compared to APPs remained unclear. Thus, a 
more detailed knowledge about the specific functions of the secreted APP ectodomains is 
essential to understand AD pathogenesis and evaluate risks of ongoing pharmacotherapy, as 
well as to elucidate APP physiology. 
There is a large body of evidence indicating that APP family proteins are multimodal proteins 
that can function as ligands via their secreted fragments or as cell surface proteins important 
for synaptic adhesion and signal transduction (Müller et al, 2017). Major insights into the 
physiological functions of APP and the related APLPs (APP like proteins) were obtained from 
knockout models (Müller et al, 2017). While most impairments of APP-KO mice emerged 
only in aged mice (Dawson et al, 1999; Lee et al, 2010; Ring et al, 2007; Seabrook et al, 
1999; Tyan et al, 2012), combined APP/APLP2 double knockout mice die shortly after birth, 
likely due to severe deficits at the neuromuscular junction (Heber et al, 2000; Klevanski et al, 
2014; von Koch et al, 1997; Wang et al, 2005). Recently generated forebrain-specific double 
knockout mice (termed NexCre cDKO), that lack APP from embryonic day 11.5 onwards in 
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excitatory forebrain neurons on a global constitutive APLP2-KO background, showed a 
severe synaptic phenotype already at young age, including reduced spine density and 
impaired LTP in the hippocampus, as well as deficits in learning and memory (Hick et al, 
2015). Interestingly, the LTP impairment of NexCre cDKO mice could be ameliorated by 
acute APPs application onto brain slices in vitro, while the molecular mechanism and 
receptor(s) mediating its function remained unknown (Hick et al, 2015).  
More recently, we showed that AAV-mediated intracranial expression of APPs can mitigate 
the A related synaptic deficits of APP/PS1 mice in vivo (Fol et al, 2016). Intracranial AAV-
APPs injections enhanced spine density, improved LTP deficits and memory, but at the 
same time also reduced soluble A levels and plaque load, likely due to enhanced A 
clearance (Fol et al, 2016). In addition, APPsα had been reported to lower A by directly 
binding to and inhibiting BACE (Obregon et al, 2012). These results raised the question of 
whether the beneficial in vivo effects of APPs are mainly due to its A lowering properties. 
Here, we asked whether APPs may also have synaptotrophic effects in an A independent 
pathology with synaptic impairments and used viral vectors to express APPsα intracranially 
in NexCre cDKO mice. Moreover, we set out to compare side-by-side the properties of 
APPsα and APPs in vivo. We demonstrate that APPsα is sufficient to fully rescue 
hippocampal spine density, to restore LTP and partially rescue spatial memory in adult 
NexCre cDKO mice. In sharp contrast, despite similar expression level, APPs failed to show 
any detectable effects on synaptic plasticity and spine density. Finally, we show that the 
CT16 domain of APPs (that is lacking in APPs) is able to facilitate LTP to the same 
extent as APPs, in a mechanism that involves functional nicotinic 7 acetylcholine 
receptors (7-nAChRs). Moreover, we show that nanomolar concentrations of APPs (but 
not APPsβ) can directly potentiate 7-nAChRs-mediated currents upon heterologous 
expression in Xenopus ooctyes and increases the apparent agonist affinity as a positive 
allosteric modulator. Collectively, our analysis identifies the 7-nAChR as a crucial 
physiological receptor for APPsα and reveals distinct in vivo roles of APPsα versus APPsβ. 
 
 
 
 
 
 
 
 
 
 5 
 
Materials and Methods 
 
Mice 
Experiments on animals were performed in accordance with the guidelines and regulations 
set forth by the German Animal Welfare Act and the Regierungspräsidium Karlsruhe, 
Germany. Generation and genotyping of NexCre cDKO mice (further referred as cDKO mice) 
were as described previously (Hick et al, 2015). Genotype of experimental animals: NexCre 
cDKO (cDKO), APPflox/floxAPLP2−/−NexCre+/T and littermate controls (LM controls), APP-WT 
(=APPflox/flox)APLP2−/−. 
 
AAV plasmid design and vector production 
The mouse APPsα coding sequence (derived from Uniprot: P12023-2) was codon optimized 
(Geneart, Germany) and then cloned under control of the synapsin promoter into a single-
stranded rAAV2-based shuttle vector, as described previously (Fol et al, 2016). Briefly, the 
bicistronic DNA constructs habour a 2A site that connects the cDNA of lckVenus and 
muAPPsα. Venus contains a lymphocyte-specific protein tyrosine kinase (lck) derived 
peptide motif which tethers it to the plasma membrane. For easy detection, an N-terminal 
double HA-tag was inserted downstream of the APP signal peptide (SP) at the N-terminus of 
APPsα. The monocistronic control vector, AAV-Venus, encodes only the yellow fluorescent 
protein Venus. All constructs were packaged into AAV9 capsids. Briefly, viral particles were 
produced by transient co-transfection of HEK-293 cells with the transfer vector containing the 
above-mentioned expression cassettes and the helper plasmid pDP9rs. 72 h following 
transfection, virions were purified and concentrated from cell lysate and supernatant by 
ultracentrifugation on a iodixanol density gradient followed by buffer exchange to 0.01% 
pluronic/phosphate-buffered saline (PBS) via a 100 kDa Amicon centrifugal filter unit. 
Genome copies in the vector stocks were determined by free inverted terminal repeat (ITR)-
specific quantitative TaqMan PCR and expressed as genomic copies per µl of concentrated 
stocks (gc/µl) as described (D'Costa et al, 2016). 
 
Stereotactic injection of AAVs 
Mice were anesthetized by intraperitoneal injection of sleep mix (Medetomedin: 500 µg/kg, 
Midazolam: 5 mg/kg, Fentanyl: 50 µg/kg in isotonic NaCl solution) and positioned on a 
stereotactic frame (World Precision Instruments, USA). Vector particles (either AAV-Venus, 
AAV-APPsα or AAV-APPsβ) were injected into the hippocampus at two injection spots per 
hemisphere using 1 μl vector stock (titer: 1 x 109 gc/µl) per spot at a rate of 0.2 μl/min. When 
injection was completed, the cannula was left to rest for 1 min to prevent efflux of viral vector 
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solution. Stereotactic coordinates of injection sites from bregma were: anteroposterior (A/P): 
−2 mm, mediolateral (M/L): ±1 mm, dorsoventral (D/V): −2.25 mm and −1.75 mm. 
Procedures were approved by the local animal care and use committee (35-9185.81/G-
304/14, Regierungspräsidium Karlsruhe, Germany) 
 
Brain samples 
Mice were sacrificed 6 weeks post-injection at 5-6 months of age. Following anesthesia, mice 
were transcardially perfused with PBS before dissection. For immunohistochemistry, one 
cerebral hemisphere was dissected and post-fixed in 4% paraformaldehyde (PFA) for 48 h 
and afterwards stored in PBS at 4°C. 40 μm coronal sections were cut using a vibratome 
(HM650V Vibratome, Thermo Fisher Scientific, USA) and collected in PBS. The other 
hemisphere was dissected to segregate hippocampus and cortex for biochemical analysis. 
Samples were then homogenized using a Polytron homogenizer (Polytron PT-MR 2100, 
Kinematica AG, Switzerland) in tissue homogenization buffer (THB, 250 mM sucrose, 1 mM 
EGTA, 20 mM Tris-HCL, pH 7.4) containing 1x protease inhibitor (Complete™ 
#04693124001, Roche, Switzerland). After centrifugation (10 min, 13,000 rpm, 4°C), the 
supernatant was collected and the protein concentration was quantified by BCA assay. 
Lysate aliquots were snap-frozen in liquid N2 and stored at −80 °C. For the detection of the 
soluble ectodomain fragments APPs, hippocampal lysates were subjected to high-speed 
centrifugation (60 min at 100,000x g) and membrane-free supernatant was used for further 
analysis.  
 
Western blot analysis 
Total brain homogenate or supernatant from ultracentrifugation (10 µg protein) was used for 
SDS-PAGE. Proteins were separated using 12% Tris-Glycin gels at 20 mA/gel in Laemmli 
buffer (0.25 M Tris, 2 M glycine and 1% SDS) and transferred to 0.45 µm PVDF membranes 
(GE Healtcare, USA) using a tank blot at 450 mA for 1 h (for samples after 
ultracentrifugation: 450 mA for 1.5 h). After blocking in PBS-T (2.5% Tween in PBS) 
containing 5% (w/v) dried milk powder at room temperature for 60 min, membranes were 
incubated with the primary antibodies at 4 °C overnight. The following antibodies were used: 
α-HA-tag (rabbit, 1:1000, #3724, Cell Signaling Technology, USA was used for total 
hippocampal homogenates or mouse, 1:1000, #2367, Cell Signaling Technology, USA used 
for analysis after ultracentrifugation), α-GFAP (rabbit, 1:3000, #173002, Synaptic Systems, 
Germany), α-Iba1 (rabbit, 1:500, #234003, Synaptic Systems, Germany), α-GFP (chicken, 
1:1000, #A10262, Thermo Fisher Scientific, USA), α-β-Tubulin (mouse, 1:10000, #MAB3408, 
Merck Millipore, USA), M3.2 (mouse, 1:1000, kind gift from Paul Mathews), Y188 (rabbit, 
1:1000, #ab32136, Abcam, UK). Membranes were then washed with PBS-T, incubated with a 
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horseradish peroxidase coupled secondary antibody (goat-α-mouse HRP, 1:10000, #115-
165-146, Dianova, Germany; donkey-α-rabbit HRP, 1:10000, #711-035-152, Dianova, 
Germany; goat-α-chicken HRP, 1:10000, #103-035-155, Dianova, Germany) washed again 
and developed using SignalFire ECL Reagent (#6883, Cell Signaling Technology, USA) or 
SignalFire™ Elite ECL Reagent (used for analysis after ultracentrifugation, #12757, Cell 
Signaling Technology, USA). Signals were detected with the BioRad Chemidoc MP imager 
(BioRad, Hercules, USA) and analyzed using BioRad Image Lab software. 
 
Immunostaining 
Slices were blocked/permeabilized in blocking buffer (5% BSA, 5% NGS, 0.4% Triton X-100 
in PBS) overnight at 4°C. To detect AAV-encoded HA-tagged HA-APPs, slices were 
incubated with α-HA antibody (rabbit-α-HA, 1:1000, #3724, Cell Signaling Technology, USA 
or mouse-α-HA, 1:1000, #H3667, Sigma-Aldrich, USA) overnight at 4°C. After three 
successive washes with PBS-T (2.5% Tween in PBS) slices were incubated in secondary 
antibody (goat-α-rabbit Cy3, 1:1500, #711-165-152, Jackson ImmunoResearch Laboratories, 
USA; goat-α-rabbit Cy5, 1:1500, #111-175-144, Jackson ImmunoResearch Laboratories, 
USA; donkey-α-mouse Cy3, 1:1500, #715-165-150; Jackson ImmunoResearch Laboratories, 
USA; goat-α-mouse Cy5, 1:1500, #A10524, Thermo Fisher Scientific, USA). For expression 
analysis HA-APPsα was coimmunostained overnight with the following primary antibodies: α-
NeuN (mouse, 1:1500, #MAB377, Merck Millipore, USA), α-GFAP (rabbit, 1:3000, #173002, 
Synaptic Systems, Germany) and α-Iba1 (rabbit, 1:500, #234003, Synaptic Systems, 
Germany). Images were taken with a Axio Observer Z1 (Zeiss, Germany) and a Leica TCS 
SP5II (Leica, Germany). 
 
Electrophysiology 
In vitro extracellular recordings were performed on acute hippocampal slices of LM controls 
stereotactically injected with the AAV-Venus (N=5) and cDKO mice injected either with AAV-
Venus (N=4), or AAV-APPsα (N=5). In a separate set of experiments cDKO mice were 
injected either with AAV-Venus (N=5) or AAV-APPs (N=5). Investigation of synaptic 
plasticity was done 7-8 weeks after AAV injection. In-between animals were housed in a 
temperature- and humidity-controlled room with a 12h light-dark cycle and had access to 
food and water ad libitum.  
 
Slice preparation 
Acute hippocampal transversal slices were prepared from isoflurane anesthetized 
individuals. Following decapitation, the brain was removed and quickly transferred into ice-
cold carbogenated (95% O2, 5% CO2) artificial cerebrospinal fluid (ACSF) containing 
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125.0 mM NaCl, 2.0 mM KCl, 1.25 mM NaH2PO4, 2.0 mM MgCl2, 26.0 mM NaHCO3, 2.0 mM 
CaCl2 and 25.0 mM glucose. The hippocampus was sectioned into 400 µm thick transversal 
slices with a vibrating microtome (VT1200S, Leica, Germany) and maintained in 
carbogenated ACSF at room temperature for at least 1.5 h. Before recording, each slice of 
the injected animals was inspected for Venus expression in area CA1 and CA3 (Axiovert 35, 
Zeiss, Germany). Slices lacking fluorescence in the recording areas were excluded from 
further analysis.  
 
Peptides and inhibitor 
Acute hippocampal slices of LM controls and cDKO mice were pre-incubated in 30 ml gently 
carbogenated ACSF containing synthetic CT16 (DAEFGHDSGFEVRHQK) or a scrambled 
CT16scr peptide (RFDQHGVEDHAFGESK) of the same aminoacid composition as a 
control. Recombinant recAPPsα was purified from the supernatant of stably transfected HEK 
cells as described (Hick et al, 2015) and was used at a concentration of 10 nM, in a custom 
made incubation chamber for 1 h at RT. Afterwards, slices were transferred into the 
recording chamber where again 30 ml of ACSF with the respective peptide was circulating in 
a closed loop during the entire experiment. In another set of experiments, the α7-nicotinic 
acetylcholine receptor antagonist (α7-nAChR) α-Bungarotoxin (BTX, Merck Millipore, 
Germany) solved in Aqua dest. was used at a final concentration of 10 nM and either co-
applied already at the step of pre-incubation (1h before TBS) together with 10 nM CT16 on 
acute slices or washed in 10 min before baseline recording started. 
 
Extracellular field recordings 
Slices were placed in a submerged recording chamber and perfused with carbogenated 
ACSF (32°C, 125.0 mM NaCl, 2.0 mM KCl, 1.25 mM NaH2PO4, 2.0 mM MgCl2, 26.0 mM 
NaHCO3, 2.0 mM CaCl2 and 25.0 mM glucose) at a rate of 1.2 to 1.5 ml/min. Field excitatory 
postsynaptic potentials (fEPSPs) were recorded in stratum radiatum of CA1 region with a 
borosilicate glass micropipette (resistance 2-4 M) filled with 3 M NaCl at a depth of 150-
200 µm. Monopolar tungsten electrodes were used for stimulating the Schaffer collaterals at 
a frequency of 0.1 Hz. Stimulation intensity was adjusted to 40% of maximum fEPSP slope 
for 20 minutes baseline recording. LTP was induced by applying theta-Burst stimulation 
(TBS: 10 trains of 4 pulses at 100 Hz in an 200 ms interval, repeated 3 times). 
Basal synaptic transmission properties were analyzed via input-output-(IO) measurements 
and short-term plasticity was examined via paired pulse facilitation (PPF). The IO-
measurements were performed either by application of a defined current values (25-250 µA) 
or by adjusting the stimulus intensity to certain fiber volley (FV) amplitudes (0.1-0.8 mV). 
Presynaptic function and short-term plasticity were assessed with the PPF paradigm by 
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applying a pair of two closely spaced stimuli in inter-stimulus-intervals (ISI) ranging from 10 
to 160 ms. 
 
 
 
Data analysis and statistics 
Data of electrophysiological recordings were collected, stored and analyzed with LABVIEW 
software (National Instruments, USA). The initial slope of fEPSPs elicited by stimulation of 
the Schaffer collaterals was measured over time, normalized to baseline and plotted as 
average ± SEM. Analysis of the PPF data was performed by calculating the ratio of the slope 
of the second fEPSP divided by the slope of the first one and multiplied by 100. The 
statistical analysis was performed using Microsoft Excel or GraphPad Prism version 6.0 
(GraphPad, USA). Data obtained between two genotypes or two different experimental 
conditions were compared using an unpaired two-tailed Student's t-test. Data including more 
than 2 different groups were analyzed using a one-Way ANOVA followed by a post-hoc 
Bonferroni´s Test. All data are indicated as mean ± SEM. Values of p<0.05 were considered 
significant and plotted as follows *p<0.05, **p<0.01, ***p<0.001.  
 
Xenopus Oocyte expression and electrophysiological recording 
The rat 7-nAChR, kindly provided by A. Nicke (Kendel et al, 2013), and the human 1-GlyR 
(Laube et al, 2000) cDNAs were subcloned into the oocyte expression vector pNKS2 . The 
original rat 7-nAChR cDNA had been provided by J. Patrick (Baylor College of Medicine, 
Houston, USA). The rat 7-nAChR or the human1-GlyR cDNA was linearized and cRNA 
was synthesized with the SP6 or T7 mMessage mMachine kit, respectively (Ambion, USA). 
For electrophysiological analysis, Xenopus laevis oocytes were injected with 50 ng of the 
cRNA in a volume of 50 nl. Oocytes were isolated and maintained as described previously 
(Laube et al, 1997) and approved by the local animal care and use committee (II25.3-
19c20/15, RP Darmstadt, Germany). 1-3 days after injection, whole-cell currents were 
recorded at -70 mV by two-electrode voltage-clamp according to (Laube et al, 2000). 
Currents were acquired at 200 Hz with a Geneclamp 500B amplifier, a Digidata 1322A 
digitizer and Clampex 9.2 software (Molecular Devices, USA). The agonists nicotine, 
acetylcholine or glycine, dissolved in bath solution, was applied either alone for 10 s or after 
15 s pre-application of the respective peptides (CT16, CT16scr, recAPPs or recAPPs) 
also dissolved in bath solution. All experiments were performed at room temperature.  
 
Data analysis and statistics 
 10 
Currents were measured with Clampfit 9.2 software (Molecular Devices, USA) and results 
were analyzed using the KaleidaGraph program (Synergy Software, USA) and GraphPad 
Prism version 6.0 (GraphPad, USA). Peak current responses to nicotine in the absence or 
presence of APPs were plotted against agonist concentration and fit with variable slope 
non-linear regression to establish agonist EC50 parameter (Laube et al, 2000). For peptide 
modulation, responses to EC50 nicotine (100µM), acetylcholine (100µM) or glycine (100 µM) 
after application were analyzed. Normalized CT16-induced fold enhancement of nicotine-
induced currents was fit with variable slope non-linear regression (GraphPad Prism version 
6.0, GraphPad, USA), yielding EC50 parameters for each individual experiment (Laube et al, 
1998). All experiments were from at least two batches of oocytes. Data were compared by 
paired two-tailed Student’s t-test. Values of p<0.05 were considered significant and plotted 
as follows *p<0.05, **p<0.01, ***p<0.001. All data are indicated as mean ± SEM. 
 
Neuronal morphology and spine density  
Iontophoretic fillings 
In brief, CA1 pyramidal cells were visualized by postfixation filling with Alexa 568 in 200 μm 
horizontal brain sections of 5-6 months old mice (see Appendix Table S1 for sex of animals). 
For iontophoretic fillings of CA1 pyramidal neurons, one brain slice at a time was placed in a 
custom-made chamber filled with cold PBS and visualized on an Olympus BX51WI fixed 
stage upright microscope (Olympus, Japan). Sharp quartz glass electrodes (Quartz 
electrodes with filament, O.D: 1.0 mm, I.D.: 0.7 mm, 10 cm length, Sutter instruments, USA) 
were pulled using the Sutter P-2000 Laser Puller. The tip of the electrode was loaded with 5 
mM Alexa 568 dye dissolved in distilled water and backfilled with 0.1 M LiCl dissolved in 
distilled water. Using a motorized 3D micromanipulator, the electrode was lowered into the 
hippocampal CA1 region under visual control using a Calcium Crimson filter cube 
(HQ580/20x, U-Q595LP (339038), HQ630/60m) while applying a negative voltage pulse (−1 
V, 1 Hz) to the electrode via a silver wire in line with a 500 MΩ resistor. When piercing of a 
cell body was observed, the cell was filled by application of a negative 1 Hz current pulse (~5 
nA) to the electrode. Filling was for 10 min or until no further filling was observed. Afterwards, 
slices were fixed for 2 days in 4 % PFA at 4 °C, washed three times in cold PBS and finally 
mounted in Mowiol.  
 
Image acquisition 
Images of filled neurons were acquired on a Leica TCS SP5II (Leica, Germany) upright 
confocal microscope. Overview images of complete neurons used for reconstruction were 
taken with a 20x objective (Apo 20x/0.75). The complete volume of one filled neuron was 
imaged with a z-step size of 1 µm and a 2048 x 2048 resolution. Basal and apical segments 
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were imaged individually with two overlapping stacks. Detailed images of dendritic segments 
and spines were acquired using a 63x objective (Apo 63x/1.4 oil) and a digital zoom of 5. To 
fullfill the Nyquist criteria for deconvolution, z-stacks of dendritic segments were captured 
with a pixel size of 80 nm and a z-step of 130 nm. Laserpower, gain and offset varied from 
cell to cell as the parameters were always chosen so that the complete range of the 
grayscale was used. Images for spine counts were deconvoluted with the AutoQuantX3 
software (Media Cybernetics, USA).  
Neuronal morphology and spine counts 
Filled CA1 pyramidal neurons were manually reconstructed using the Neurolucida software 
(MicroBrightField, USA) by an experimentator blind to genotype and injected viral vector. 
Neurons were only included into Sholl analysis if they showed a completely filled apical or 
basal tree and well defined dendritic endings. The morphometric Sholl analysis was done 
using the NeuroExplorer software (MicroBrightField, USA). In short, a series of concentric 
spheres (centered around the soma) was drawn with an intersection interval of 30 µm and 
the number of dendrites crossing each sphere, as well as the dendritic length in between 
each sphere was calculated. This analysis was done separately for basal and apical 
dendrites and was plotted against the distance from the soma. For evaluation of basal 
dendritic spine density, at least 3 different randomly chosen dendritic segments of the basal 
dendritic arbour were imaged. They had to fulfil the following criteria: (1) Lie mostly 
horizontally to the slice surface, (2) be at least 20 µm away from the soma, (3) have a 
comparable thickness. The minimum basal dendritic length imaged per neuron was 100 µm. 
For evaluation of midapical dendritic spine density, at least 3 different dendritic segments of 
the apical tree were imaged. Midapical was defined as the middle third of the length of the 
apical dendrite measured from the origin of the apical dendrite from the soma to the endpoint 
of the tufts. Dendritic segments used for evaluation had to fulfil the following criteria: (1) be of 
second or third order to assure comparable shaft thickness, (2) lie in the middle third of the 
main apical dendrite (3) be longer than 10 µm. The minimum midapical dendritic length 
imaged per neuron was 100 µm. Files in the ND2 format were imported into ImageJ (NIH) 
using the BioFormats Importer. After adjusting, images were saved in the TIFF format. 
Dendritic spines were manually counted using the Neurolucida and NeuroExplorer software 
(MicroBrightField, USA) following the criteria of Holtmaat (Holtmaat et al, 2009) with minor 
modifications: (1) All spines that protruded laterally from the dendritic shaft and exceeded a 
length of 0.4 µm were counted. (2) Spines that protruded into the z-plane were only counted 
if they exceeded the dendritic shaft more than 0.4 µm to the lateral side. (3) Spines that 
bisected were counted as two spines. (4) Spines had to be at least 10 µm away from 
branching points and the soma. Spine density was expressed as spines per µm of dendrite. 
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Prior to statistical analysis and blind to genotype, neurons were excluded if the image quality 
(poor signal to noise ratio) was not sufficient for counting of spines or for deconvolution. 
 
Golgi staining 
Golgi staining was done using the Rapid Golgi Staining Kit (FD NeuroTechnologies, USA) 
according to the manufacturer’s instructions. All procedures were performed under dark 
conditions. One hemisphere of each mouse was used for Western blot analysis and the other 
hemsiphere for Golgi staining (see Appendix Table S1 for sex of animals). Hemispheres 
were immersed in 2.5 ml mixtures of equal parts of kit solutions A and B and incubated at 
room temperature for 2 weeks. After 24 h solution A + B was renewed. Afterwards, brain 
tissues were stored in solution C at 4°C for at least 72 h, once exchanged after 24 h. Brains 
were snap-frozen on dry ice and coronal sections of 100 μm were cut with a cryotome (Hyrax 
C50, Zeiss, Germany). Each section was mounted with Solution C on an adhesive 
microscope slide pre-coated with 1% gelatin/0.1% chrome alum on both sides and stained 
according to the manufacturer´s protocol with the exception that RotiClear (Roth, Germany) 
was used instead of xylene. Finally, slices were cover-slipped with Permount (Thermo Fisher 
Scientific, USA). 
 
Imaging and analysis of spine density after Golgi staining 
Imaging of second- or third-order dendritic branches of hippocampal pyramidal neurons of 
area CA1 was done with an Axio Observer Z1 (Zeiss, Germany) for Golgi-stained neurons 
using a 63x oil objective. Z-stack thickness was hold constant at 130 nm. The number of 
spines was determined per micrometer of dendritic length (in total 100 μm per neuron) at 
apical and basal compartments using Neurolucida software (MicroBrightField, USA). Spines 
in the area around branching points and the soma were excluded from analysis. Five animals 
per genotype and 3-4 neurons per animal were analysed blind to genotype and injected viral 
vector. 
 
Behavioral analysis 
Animals 
Mice (cDKO + AAV-APPsα: 9M + 9F, cDKO + AAV-Venus: 8M + 10F, LM control + AAV-
Venus: 12M + 10F) were housed under a 12/12h light-dark cycle (lights on at 20:00) in 
groups of 2-5, unless individual housing was required by experimental protocols or to prevent 
fighting. Testing occurred during the dark phase under dim light (approximately 12 lux). Mice 
were transferred to the testing room 30 min before testing. Procedures were approved by the 
Veterinary Office of the Canton of Zurich (license 44/2015). 
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Behavioral procedures 
Morris Water Maze place navigation. The round white poly-propylene pool had a diameter of 
150 cm with 68 cm high walls. It was filled with water (24-26° C, depth 15 cm), rendered 
opaque by addition of 1 l of milk (UHT whole milk 3.5% fat, Coop, Switzerland). The white 
quadratic goal platform (14x14 cm) was made of metallic wire mesh. It was hidden 0.5 cm 
below the water surface in the center of one of the 4 quadrants, 30 cm from the side wall. 
Salient extra-maze cues were placed on the walls of the testing room. Animals performed 30 
training trials (max. duration 120 s), 6 per day with intertrial intervals of 30-60 min and 
varying starting positions. During the first 18 trials the hidden platform was held in the same 
position (acquisition phase) and then moved to the opposite quadrant for the remaining 12 
trials (reversal phase). The first 60 s of the first reversal trial served as probe trial to test for 
spatial retention. Time spent in a circular target zone comprising 12.5% of the pool surface 
was compared with corresponding control zones in adjacent quadrants. 
 
Data analysis and statistics 
The path of moving mice was tracked using Noldus EthoVision 3.1 (Noldus, Netherlands). 
For analysis all data were imported in custom programmed software Wintrack 
(www.wintrack.ch; Wolfer et al, 2001). Data were evaluated using an ANOVA model with 
genotype (cDKO + AAV-APPs, cDKO + AAV-Venus, LM control + AAV-Venus) and sex as 
between subject factors. Within subject factors were added as needed to explore the 
dependence of genotype effects on place or time. Significant interactions and where 
necessary significant main effects were further explored by pairwise t-tests or by splitting the 
ANOVA model, as appropriate. Variables with strongly skewed distributions or strong 
correlations between variances and group means were subjected to Box-Cox transformation 
before statistical analysis. The significance threshold was set at 0.05. The false discovery 
rate (FDR) control procedure of Hochberg was applied to groups of conceptually related 
variables within single tests to correct significance thresholds for multiple comparisons. 
Similarly, FDR correction was applied during post-hoc testing. As genotype and treatment 
effects were independent of sex, the sex factor is not reported in results and figures. 
Statistical analyses were run using R version 3.2.3 complemented with the packages psych 
and moments. 
 
For further methods related to EV Figures see Appendix Supplementary Methods 
 
 
Results 
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AAV‑APPsα injection mediates efficient and neuron specific expression of APPsα in 
the hippocampus of cDKO mice 
To investigate whether APPsα is able to rescue the synaptic deficits of NexCre cDKO (further 
referred to as cDKO) animals in vivo, APPsα was expressed in the adult brain using 
stereotactic injection. We employed an AAV9-based bicistronic vector (AAV-APPsα; Figure 
1A) coding for Venus and codon-optimized HA-tagged murine HA-APPsα that was inserted 
behind the APP signal peptide (SP). The HA-APPsα reading frame was fused to Venus by a 
T2A site to enable tracking of transduced cells. Expression was driven by the neuronal 
synapsin promoter. Monocistronic AAV-Venus vector served as a control (AAV-Venus; 
Figure 1A). Adult cDKO animals (aged 4-5 months) were either injected with AAV-APPsα or 
AAV-Venus control vector, whereas littermate control mice (LM control) received only AAV-
Venus. Thus, comparison of AAV-Venus injected cDKO mice with AAV-Venus injected LM 
controls was expected to yield similar synaptic impairments as previously observed for 
uninjected cDKO mice (Hick et al, 2015). Vectors were bilaterally injected (dose: 
1.0 x 109 gc/µl per injection spot) into the stratum lacunosum moleculare region of the dorsal 
hippocampus and into the dentate gyrus (Figure 1B). To evaluate Venus and APPsα 
expression, animals were sacrificed 6 weeks post-injection and brain samples were analysed 
by Western blotting and immunohistochemistry using an HA-tag-specific antibody. Analysis 
of serial anteroposterior coronal brain sections (Bregma -1.10 to Bregma -2.70; see Figure 
EV1C) revealed widespread expression of APPsα in the hippocampus and, to a considerably 
lower extent, also in adjacent cortical areas (Figure 1C and EV1C). Along the longitudinal 
(dorsal-ventral) axis of the hippocampus APPsα expression was much more pronounced in 
the dorsal region, whereas expression was not detectable in the ventral hippocampus (Figure 
EV1C).  
As Venus contained a membrane anchor, we observed prominent accumulation in dendritic 
regions, whereas HA-APPsα staining was intense in intracellular membrane compartments 
consistent with the transport of APPsα within the secretory pathway to the cell surface for 
secretion (see also Figure EV2D and E for co-localization with ER and Golgi markers). In the 
CA3 region APPs expression appeared slightly lower compared to the expression obtained 
in pyramidal cells of the subiculum, the CA1 (Figure 1C) and the CA2 regions. Consistent 
with previous studies (Jackson et al, 2016), we noted that APPsα was detectable in HEK 
cells transfected with synapsin promoter driven AAV constructs (see Figure EV2A), likely due 
to AAV plasmid overload. In vivo, however, AAV-APPsα expression was restricted to 
neurons, as shown by double immunofluorescence staining against the HA-tag and the 
neuronal marker NeuN (Figure 1D and E). Consistently, no overlapping expression pattern 
was detectable in astrocytes (GFAP; Figure 1F) and microglia (Iba1; Figure 1G). The AAV-
Venus expression pattern obtained from injections of control vector was largely similar to that 
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of AAV-APPsα (Figure EV1C). Western blot analysis of hippocampal homogenates, using 
the M3.2 antibody, confirmed efficient AAV-mediated APPsα expression in injected animals 
(Figure 1H). Note that antibody M3.2 is directed against an epitope located between the - 
and -secretase site and recognizes endogenous APP species (APP full length and APPsα) 
that are still expressed by interneurons and glia in cDKO mice (see Hick et al, 2015) and 
vector-derived AAV-APPsα. Collectively, our data demonstrate that AAV-APPsα injection 
results in efficient and neuron specific expression of APPsα throughout the dorsal 
hippocampus.  
 
Impaired synaptic plasticity and reduced spine density of APP/APLP2 cDKO mice are 
rescued by APPsα expression in the adult brain 
Having demonstrated that HA-APPsα is efficiently expressed in the hippocampus of injected 
animals we evaluated whether APPsα is sufficient to rescue impairments in functional 
network activity that were previously reported for cDKO mice (Hick et al, 2015). After 20 min 
of baseline recording we induced long-term potentiation (LTP) at the Schaffer collateral to 
CA1 pathway by application of theta burst stimulation (TBS) in acute hippocampal slices of 
mice that had been injected with viral vectors 6 weeks earlier (at 4-5 months of age). 
Consistent with our previous results (Hick et al, 2015) AAV-Venus injected cDKO mice 
exhibited significantly lower induction and maintenance of LTP (n=25 slices), as compared to 
AAV-Venus injected LM controls (n=23; Figure 2A). AAV-Venus injected LM control mice 
showed a potentiation of 156.69 ± 4.75% (t75-t80 after start of baseline recording) that was 
significantly reduced to only 128.12 ± 3.41% in AAV-Venus injected cDKO mice (one-way 
ANOVA followed by Bonferroni’s post-hoc test, ###p<0.001; Figure 2B). In contrast, the LTP 
curve recorded from acute slices of AAV-APPsα injected cDKO mice (n=24) closely 
overlapped with that of AAV-Venus injected LM controls (Figure 2A). Quantification of the 
last five minutes of recording revealed that APPsα rescued LTP deficits of cDKO mice to a 
level statistically indistinguishable from that of Venus injected LM controls (t75–80: 150.34  
3.55%, nsp>0.05; Figure 2B,). While basal synaptic transmission was comparable in all 
groups (see Figure EV3A and B), presynaptic function evaluated by paired pulse facilitation 
(PPF; Figure 2C) was significantly impaired in AAV-Venus injected cDKO mice at the 10 ms 
(#p<0.05) and 20 ms (#p<0.05) inter-stimulus intervals (ISI) in comparison to AAV-Venus 
injected LM controls. Strikingly, AAV-APPsα treatment lead to a highly significant rescue of 
short-term synaptic plasticity in cDKO mice as evidenced by PPF values statistically 
indistinguishable from LM controls (Figure 2C). 
 
Next, we evaluated spine density as a correlate of excitatory synapses. To visualize neuronal 
morphology and spine density we performed iontophoretic postfixation filling with a 
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fluorescent dye of hippocampal CA1 pyramidal cells in brain slices from injected adult mice 
(aged 5-6 months). Consistent with our previous study (Hick et al, 2015), we confirmed a 
prominent reduction in spine density both in basal (100.00 ± 3.41 vs. 88.77 ± 3.10 spines/μm, 
#p<0.05) and in midapical dendrites (100.00 ± 3.57 vs. 82.08 ± 4.73 spines/μm, #p<0.05) of 
AAV-Venus injected cDKO CA1 neurons as compared to AAV-Venus injected LM controls 
(Figure 2D-F). In contrast, spine density of AAV-APPsα injected cDKO mice did not 
significantly differ from that of AAV-Venus injected LM control neurons, indicating that APPsα 
expression fully restored spine density in CA1 neurons. Collectively, these data demonstrate 
that acute expression of APPsα in adult mice is sufficient to rescue morphological and 
functional synaptic deficits in cDKO animals.  
 
APPsα ameliorates dendritic branching abnormalities of cDKO animals 
Prompted by the effect of APPsα on spine density we further evaluated its influence on the 
overall morphology and complexity of hippocampal CA1 neurons (Figure 3). In view of their 
different morphology and connectivity, basal and apical dendrites of CA1 neurons were 
studied separately. Neurons of AAV-Venus injected cDKO mice showed a significantly 
reduced total dendritic length and branching (as assessed by the number of nodes) in both 
basal and apical dendrites compared to AAV-Venus injected LM controls (Figure 3A-F). 
Impairments were readily apparent when visually inspecting reconstructed images of 
individual neurons (Figure 3A). 
Although, total dendritic length was not significantly increased by APPsα expression in cDKO 
animals, the total number of nodes was significantly increased in basal dendrites of neurons 
from AAV-APPsα injected cDKO mice (Figure 3D) compared to injected LM controls (one-
way ANOVA followed by Bonferroni’s post-hoc test, *p<0.05). To investigate whether 
changes in dendritic complexity may be more pronounced in distinct dendritic subregions we 
performed morphometric Sholl analysis. We plotted the dendritic length measured within 
circles centered on the soma against the distance from the cell body (see scheme in Figure 
3B). In this analysis an increase in dendritic length per sphere corresponds to an increased 
dendritic complexity. Comparison of dendritic complexity between pyramidal neurons from 
AAV-Venus injected cDKO and LM control mice revealed an overall reduced dendritic 
complexity in cDKO neurons, both in basal (Figure 3G) and apical dendrites (Figure 3H). 
Branching deficits of basal dendrites from Venus injected cDKO neurons were most 
pronounced in proximal dendritic segments (60-90 µm from the soma). In apical dendrites 
both proximal regions (60-180 µm) and midapical regions (300 µm, 330 µm) were less 
complex. Interestingly, neurons of AAV-APPsα injected cDKO mice exhibited an intermediate 
curve with partially restored dendritic complexity. Sholl analysis revealed significantly 
increased dendritic complexity in proximal regions (60 μm) of basal dendrites of AAV-APPsα 
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injected cDKO neurons (repeated measures ANOVA followed by Sidaks’s post-hoc test, 
*p<0.05; Figure 3G). Likewise, in apical dendrites of cDKO mice injected with AAV-APPsα, 
dendritic length was significantly increased at a distance of 300 µm (**p<0.01) and 330 µm 
(**p<0.01) as compared to neurons of AAV-Venus injected LM controls. Together, these data 
indicate that APPsα ameliorates branching deficits of cDKO mice at distinct dendritic regions. 
 
APPsα improves spatial learning and spatial memory in cDKO mice 
To evaluate whether improved synaptic density and plasticity is also reflected at the 
behavioural level we assessed spatial learning and memory in the Morris water maze (MWM) 
place navigation task (Figure 4). To this end, cDKO mice were either injected with AAV-
Venus (n=18, red circles) or with AAV-APPsα (n=18, green circles) at 4-5 months of age and 
tested 2 months later at 6-7 months of age. For comparison, LM controls were injected with 
AAV-Venus (n=22, white circles). While swim speed was comparable in all groups (Figure 
4A), we observed an overall impaired performance in AAV-Venus injected cDKO mice both 
during acquisition and reversal training. Although all three groups of mice did show learning, 
escape latencies (Figure 4B) and swim path lengths (Figure 4C) were significantly increased 
in Venus injected cDKO mice compared to Venus injected LM controls, especially at day 2 
and 3 of acquisition, learning and for the last trials of reversal learning. These data are highly 
consistent with and confirm the deficit in spatial learning observed previously in uninjected 
cDKO mice (Hick et al, 2015). Overall, APPsα expression in cDKO mice lead to an 
intermediate performance with significantly improved learning during the reversal phase. 
AAV-APPsα expression in cDKO mice significantly decreased escape latency (**p<0.01; 
Figure 4B) and swim path length (*p<0.05; Figure 4C) at day 5 of reversal learning, as 
compared to AAV-Venus injected cDKO mice. During the probe trial that assesses spatial 
reference memory, analysis of time [%] spend in the target zone (Figure 4D) reveals a 
significant overall group x place effect (F(2, 46)=9.095, p=0.0005). AAV-Venus injected 
cDKO mice were strongly impaired in comparison to AAV-Venus injected controls 
(###p<0.001) and failed to prefer the trained target zone. Time spend in the target zone was 
not significantly different from chance level. Strikingly, AAV-APPsα expression substantially 
improved probe trial performance in cDKO mice compared to Venus injected cDKO mice 
(**p<0.01). Moreover, AAV-APPsα injected cDKOs showed a highly significant preference for 
the trained target zone over adjacent quadrants (**p<0.01). Together these data indicate that 
expression of APPsα in the adult hippocampus substantially improved spatial reference 
memory. 
 
APPsβ does not rescue LTP or spine density in vivo 
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During AD BACE expression is upregulated (Ahmed et al, 2010; Holsinger et al, 2002) 
leading to increased amyloidogenic APP processing and thus increased APPsβ levels. 
Although APPsβ has been reported to be less potent in assays of neuroprotection in vitro 
(Barger & Harmon, 1997; Copanaki et al, 2010; Furukawa et al, 1996), the molecular basis of 
this property has remained elusive and its in vivo role is currently unknown. We therefore 
evaluated in a separate set of experiments whether APPsβ, being only 16 amino acids 
shorter compared to APPsα (see Figure 5B) might also be able to rescue the impairments of 
cDKO mice. Briefly, we stereotactically injected cDKO mice and LM controls (4-5 months of 
age) with AAV-Venus or a bicistronic vector coding for Venus and HA-tagged murine APPsβ 
(AAV-APPsβ; Figure 5A). Immunohistochemistry of serial brain sections indicated that 
injection of AAV-APPsβ yielded a comparable expression level and distribution to that 
obtained for HA-APPsα (Figure 5C and EV1C). Western blot analysis of total hippocampal 
homogenates (containing cell bound and secreted proteins), using an HA-tag specific 
antibody further confirmed similar (and statistically not significantly different) levels of HA-
APPsß and HA-APPsα expression upon injection of the respective AAVs (unpaired two-tailed 
Student’s t test, nsp>0.05; Figure 5D and E). Ultracentrifugation (UC) of the same 
hippocampal homogenates was used to specifically detect soluble HA-APPsα and HA-
APPsβ (Figure 5D, lower boxed panels) and yielded comparable levels of APPsα and APPsβ 
in UC supernatants (unpaired two-tailed Student’s t test,  nsp>0.05; Figure 5D and E). 
Transfection of HEK cells (Figure EV2A) with the APPsα or APPsβ encoding AAV plasmids 
or transduction of cultured neurons with either of the AAV vectors (Figure EV2B), further 
confirmed efficient and comparable secretion of APPsα or APPsβ, as evidenced by Western 
blot analysis of cell supernatants (Figure EV2A and B). 
 
Strikingly, despite comparable levels of expression and secretion, soluble APPsβ failed to 
exert any detectable effects on basal synaptic transmission (Figure EV3C and D) or synaptic 
plasticity in recordings of cDKO slices at 5-6 months of age (Figure 5F-H). AAV-APPsβ 
injected cDKO mice showed superimposable LTP curves compared to Venus injected cDKO 
mice. Potentiation at t75-80 min after start of baseline recording was not significantly different 
(cDKO + AAV-Venus: 125.58± 2.69% vs. cDKO + AAV-APPsβ: 124.42± 1.96%, nsp>0.05, 
unpaired two-tailed Students t-test). Moreover, also in the PPF paradigm AAV-APPsβ 
expression did not lead to any detectable difference compared to AAV-Venus control 
injections (Figure 5H). Likewise, and consistent with electrophysiological analysis, AAV-
APPsβ failed to rescue spine density deficits of cDKO mice determined upon Golgi staining. 
While AAV-Venus control-injected cDKO revealed again a significant reduction in spine 
density in basal and in apical dendrites as compared to Venus injected LM controls (Figure 5 
I-K), spine density was comparable and statistically indistinguishable in AAV-Venus and 
 19 
APPsβ injected cDKO mice. Basal dendrites from AAV-Venus and AAV-APPsβ injected 
cDKO mice showed a similar and statistically not significantly different reduction in spine 
density of 14% (LM control + Venus: 100 ± 2.84 vs. cDKO + APPsβ: 85.99 ± 3.51 spines/μm, 
*p<0.05) and 12% (LM control + Venus: 100 ± 2.84 vs. cDKO + APPsβ: 88.39 ± 3.26 
spines/μm, ****p<0.0001), respectively (Figure 5J). In midapical dendritic segments spine 
density was reduced by 24% in AAV-Venus injected cDKO animals (LM control + Venus: 100 
± 4.01 vs. cDKO + APPsβ: 76.05 ± 2.097 spines/μm) or by 18% (LM control + Venus: 100 ± 
4.01 vs. cDKO + APPsβ: 82.40 ± 3.28 spines/μm) in AAV-APPsβ injected animals, 
respectively (Figure 5K). Together, these data indicate a striking difference in the in vivo 
properties of secreted APPs, with APPsα ameliorating morphological and functional synaptic 
deficits of cDKO mice, while APPsβ had no effect.  
 
APPsα fascilitates LTP via its C-terminal CTα16 domain  
Prompted by these results, we now focused on the 16 amino acids domain (CT16) that 
distinguishes APPsα from APPsβ (Figure 5B and L-Q). Previously, we had demonstrated that 
a short incubation of slices with recombinant APPsα (recAPPsα) is sufficient to largely rescue 
the LTP deficits of cDKO mice (Hick et al, 2015). To determine whether this acute function of 
APPsα is mediated by the CT16 domain, we now pre-incubated cDKO slices for 60 min at 
room temperature either with a synthetic CT16 peptide (10 nM), or with CTα16scr (10 nM), a 
scrambled peptide of the same aminoacid composition. After 20 min of baseline recording 
LTP was again induced by TBS. During the whole measurement, the peptides diluted in 
ACSF were circulating in a closed-loop system. Strikingly, we found that the application of 
CTα16 potently facilitated LTP over the whole recording period (Figure 5L and M) including 
the early phase of post tetanic potentiation (t20-25, CTα16: 191.49 ± 8.82% vs. CTα16scr: 
165.12 ± 8.82%, *p<0.01; Figure 5L and M) and led to a highly significant increase in LTP 
values 60 min after the beginning of baseline recording (t75-80, CTα16: 148.08 3.65% vs 
CTα16scr: 132.184.26%, **p<0.01; Figure 5L and M). In contrast, LTP values obtained for 
CTα16scr were very similar to those after AAV-Venus injection into cDKO mice (t75-80, 
128.12 ± 3.41%; Figure 2B). CT16 peptide application also significantly improved and 
restored PPF of cDKO slices (Figure 5N) to values comparable to that obtained for AAV-
Venus injected LM control mice (see Figure 2C). Next, we directly compared the activity of 
CT16 and recAPPsα (Figure 5O-Q) that was purified from stably transfected HEK cell 
supernatants. We found that CT16 application (10 nM) was as potent as recAPPsα (10 nM) 
in rescuing both the LTP (t75-80, APPs: 146.15 ± 4.21% vs. CT16: 148.08 ± 3.65%, 
nsp>0.05) and PPF deficit of cDKO slices. Values obtained were statistically indistinguishable 
(Figure 5O and P). Together, these data identify the CT16 domain of APPsα as sufficient to 
mediate the functions of APPsα for enhancing synaptic plasticity in vitro. 
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Inhibition of α7-nAChR by BTX blocks APPs mediated effects on LTP 
While elevated (micromolar) Aβ concentrations and aggregated Aβ species exert an 
inhibitory effect on synaptic function (Gu & Yakel, 2011; Kamenetz et al, 2003; Shankar et al, 
2007) picomolar concentrations of soluble Aβ have previously been demonstrated to 
enhance LTP and PTP in a mechanism dependent on the activity of α7 nicotinic 
acetylcholine receptors (α7-nAChRs; Puzzo et al, 2011; Puzzo et al, 2008). As the CTα16 
domain of APPsα overlaps with the N-terminus of A we therefore tested whether signalling 
by α7-nAChR may mediate the LTP fascilitating functions of APPsα. First, we hypothesized 
that if α7-nAChRs are crucially involved in the LTP facilitating effect of APPs, 
pharmacological block of α7-nAChR should impair LTP in LM control mice that still express 
APP and APPsα. Indeed, treatment of slices with 10 nM α-bungarotoxin (α-BTX), a specific 
inhibitor of α7-nAChRs significantly reduced LTP during the induction phase (t20-25, LM 
control: 184.01 ± 5.59% vs. LM control + BTX: 158.04 ± 8.35%, *p< 0.05) and the 
maintenance phase (t75-80, LM control: 147.25 ± 3.87% vs. LM control + BTX: 131.24 ± 
4.99%, *p<0.05; Figure 6A and B). Values obtained after BTX treatment were very similar to 
those of CT16scr treated cDKO slices (compare to Figure 5L and M, CT16scr treated cDKO 
slices: 132.184.26%).  
 
Next, we tested how α-BTX affects the induction of LTP by exogenous application of 
recAPPsα or CTα16 (Figures 6,C-G and EV4). When α-BTX was added after the incubation 
of slices with either recAPPsα or CTα16 30 min before TBS (Figure EV4A, scheme) we 
observed only a small but not significant reduction in LTP (Figure EV4B-E). In contrast, if α-
BTX was co-applied together with recAPPsα for 1 h before TBS (Figure 6C, scheme), this 
lead to a significant inhibition as compared to recAPPsα treatment alone (Figure 6D and E) 
both during the LTP induction phase (t20-25, recAPPs: 168.49 ± 7.20% vs. recAPPs + 
BTX: 142.57 ± 7.75%, *p<0.05; Figure 6D and E) and the LTP maintenance phase (t75-80, 
recAPPs: 135.59 ± 3.81% vs recAPPs: + BTX: 118.58 ± 5.51%, *p<0.05; Figure 6D and 
E). Similarly, if α-BTX was co-applied together with the CT16 peptide for 1 h before TBS 
(Figure 6F and G) this lead to a significant inhibition as compared to CT16 treatment alone 
both during the LTP induction phase (t20-25, CT16: 176.23 ± 4.69% vs. CT16 + BTX: 
153.75 ± 5.05%, *p<0.05; Figure 6F and G) and the LTP maintenance phase (t75-80, 
CT16: 144.37 ± 2.34% vs CT16 + BTX: 129.24 ± 3.40%, **p<0.01; Figure 6F and 
G).Together, these data suggest that APPsα exerts its functions on LTP mainly via the 
CTα16 domain in a mechanism depending on α7-nAChR function. Further studies are 
needed to address whether improvements in spine density and behavior that we observed 
upon AAV-APPsα re-expression might also depend on α7-nAChR function. 
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APPsα shows high-affinity allosteric potentiation of α7-nAChR expressed in Xenopus 
oocytes 
To investigate whether CT16 can modulate 7-nAChRs directly, homomeric 7-nAChRs 
were expressed in Xenopus laevis oocytes, and nicotine- or acetylcholine-induced currents 
at submaximal EC50 agonist concentration (100 µM) were measured either alone or after pre-
application of CT16 by two-electrode voltage clamp. Upon application of 100 nM of CT16 
alone, no activation of 7-nAChRs was detectable (data not shown). Remarkably, 100 nM of 
CT16 significantly potentiated both, nicotine- and acetylcholine-induced currents with a 2.58 
± 0.42-fold (n=8) and 3.01 ± 0.96-fold (n=7) enhancement of 7-nAChRs responses, 
respectively (paired two-tailed Students t-test, *p<0.05; Figure 7A and B). In contrast, no 
significant effect of 100 nM CT16scr on nicotine-induced currents could be detected (1.00 ± 
0.06-fold increase, paired two-tailed Students t-test, n=5; nsp>0.05; Figure 7A and B). Dose-
response analysis of CT16 concentrations between 1 and 100 nM yielded an EC50 value for 
CT16 of 10.7 ± 4.6 nM with an hill-coefficient of 2.1 ± 0.3 for 7-nAChRs (n=4; Figure 7C). 
To establish if the physiological APPs fragment that contains the CT16 sequence at the C-
terminus can also modulate 7-nAChRs, we tested the effect of 20 nM recAPPs, a 
concentration close to the 10 nM that facilitated LTP in slices, on nicotine-gated currents 
(Figure 7D-F). Indeed, 20 nM recAPPs significantly potentiated nicotine-induced currents 
(3.35 ± 0.81-fold enhancement, paired two-tailed Students t-test, n=4; *p<0.05) to a similar 
extent as seen with 100 nM of CT16 (Figure  7D and E, see Figure 7A for comparison). 
This effect could be specifically blocked by BTX (Figure 7D). Notably, and consistent with 
experiments in slices, no significant potentiation was seen upon pre-application of 20 nM 
recAPPs (1.32 ± 0.18-fold enhancement, paired two-tailed Students t-test, n=5, nsp>0.05; 
Figure 7D and E). As a further control, we investgated whether APPs may also modulate 
other pentameric ion channels. However, neither recAPPs nor CT16 had any effects on 
the structuraly related homomeric 1-GlyR (Figure EV5), indicating that APPs specifically 
acts on 7-nAChRs. Next, to gain further mechanistic insight, we analyzed nicotine dose-
responses of 7-nAChRs in the presence of a potentiating concentration of recAPPs to see 
how APPs modulates 7-nAChRs (Figure 7F). Strikingly, 20 nM recAPPs shifted the 
nicotine dose-response curve to the left and lead to an approximately 2-fold significant 
decrease in the EC50 of nicotine (40.3 ± 6.0 µM) as compared to recAPPs-free conditions 
(EC50 of 80.5 ± 12.7 µM, paired two-tailed Students t-test, n=5, *p<0.05) without affecting the 
hill-coefficient (3.3 ± 0.5 vs. 3.7 ± 0.9, paired two-tailed Students t-test, nsp>0.05) and the 
maximal inducible nicotine currents (Figure 7F). Together, these data indicate that APPs 
 22 
acts as a potent (nanomolar range) positive allosteric modulator of 7-nAChRs by increasing 
the apparent agonist affinity.  
 
 
Discussion 
In this study we provide compelling evidence for distinct functional roles of the two secreted 
APP ectodomain fragments APPsα and APPs in vivo and provide functional insight into the 
underlying mechanism. Long-term AAV mediated expression of either APPsα or APPs in 
the hippocampus of adult NexCre cDKO (cDKO) mice revealed several important new 
findings: (1) In vivo expression of APPsα efficiently rescued deficits in spine density, synaptic 
plasticity (LTP and PPF) and spatial reference memory of cDKO mice. (2) In contrast to 
APPsα, APPs expression had no detectable effects on spine density and synaptic plasticity 
in cDKO mice indicating distinct functional roles in the adult CNS. (3) The C-terminal 16 
amino acids (CT16) of APPsα proved sufficient to enhance LTP to the same extent as full 
length APPsα. (4) Nanomolar concentrations of APPsα and CTα16 function as potent 
positive allosteric modulators of α7-nAChRs in vitro increasing the apparent agonist affinity. 
(5) Pharmacological blockade of α7-nAChRs impaired the APPsα (or CTα16) induced LTP 
facilitation, thus identifying α7-nAChRs as physiological APPsα receptors that are involved to 
mediate its LTP enhancing effects. 
Our previous studies indicated that LTP deficits of cDKO mice can be rescued by acute 
application of nanomolar amounts of APPsα, but not APPs, in vitro. Despite this, it remained 
unclear whether these acute in vitro effects observed for a short time of recording would also 
be relevant in vivo and whether reduced spine density and behavioural deficits might also be 
rescued. Lastly, the mechanism by which APPsα regulates LTP including the relevant 
receptor was unknown. In principle, synaptic deficits of cDKO mice may either arise from 
developmental deficits such as impaired synaptogenesis that could lead to miswired circuits 
or may be due to a lack of APP (or APLP2) mediated functions in the adult brain. To address 
these questions and to assess the specific role(s) of the secreted ectodomains APPsα and 
APPs we used a reverse genetic approach employing AAV mediated re-expression of 
APPsα or APPs in the hippocampus of adult cDKO mice. Expression of the AAV-Venus 
control vector in cDKO mice or littermate controls fully reproduced and confirmed the 
phenotype of cDKO mice (Hick et al, 2015) including reduced dendritic complexity (Figure 3) 
and spine density of CA1 neurons (Figure 2), deficits in synaptic plasticity (Figure 2), as well 
as impaired spatial memory (Figure 4). This indicates that the cDKO phenotype is robust and 
that AAV vectors are suitable to confer neuron-specific, long lasting and widespread 
expression throughout the dorsal hippocampus (see Figure 1 and EV1). Using this in vivo 
reconstitution approach we show that APPsα is not only able to acutely modulate synaptic 
 23 
strength when applied in vitro (Hick et al, 2015), but has the ability to mediate a long-lasting 
rescue of synaptic plasticity, with facilitating effects on both the induction and maintenance 
phase of LTP. Moreover, we show that APPsα re-expression rescued spine density, a 
correlate of excitatory synapses. These data are perfectly in line with our recent observation 
that a lack of APP and thus APPsα in APP-KO mice leads to impairments in structural spine 
plasticity in the cortex (Zou et al, 2016). While synaptic plasticity and spine density were 
completely restored, APPsα expression led only to a partial rescue of dendritic complexity of 
CA1 neurons with effects most pronounced close to the soma and in the midapical region of 
apical dendrites. These more subtle effects might in part be related to a potential non-uniform 
secretion of APPsα along dendritic regions of individual neurons that may become limiting at 
more distant regions. Alternatively, it is conceivable that APPsα is not sufficient to fully 
restore neurite outgrowth and dendritic arbours due to an inability to compensate early 
developmental defects or an additional requirement for APLP2 (Hick et al, 2015; Weyer et al, 
2014). In this regard neither deficiency of APP nor APLP2 alone results in reduced dendritic 
complexity in young adult knockout mice (Lee et al, 2010; Midthune et al, 2012; Tyan et al, 
2012) while a combined absence in cDKO mice profoundly impairs neuronal morphology and 
total neurite length (Hick et al, 2015; Weyer et al, 2014 and this study) indicating a combined 
role of APP and APLP2 for dendritic complexity. Although the underlying mechanism is still 
unknown, it appears likely that domains conserved between APP and APLP2 (and not 
divergent sequences as those close to the secretase sites) are involved.  
 
The ability of synapses to undergo long-term potentiation is considered as a cellular 
mechanism underlying learning and memory (reviewed by Korte & Schmitz, 2016). Indeed, 
restoration of LTP by APPsα at the CA3/CA1 pathway was associated with a significantly 
improved performance in water maze place navigation during reversal learning (Figure 4B 
and C) and a substantial increase of spatial reference memory, as assessed during the 
probe trial. In mice, emotional reactions to the swim stress are a limiting factor for 
performance during task acquisition, that becomes less relevant during reversal learning as 
mice get habituated to the stressfull experience (Lipp & Wolfer, 1998; Strange et al, 2014). 
The dorsal hippocampus known to mediate spatial processing (Strange et al, 2014) was 
efficiently targeted by AAV-APPs injections whereas AAV-APPs was undetectable in 
ventral portions of the hippocampus (Figure EV1C) that mediate emotional responses. Thus, 
a failure to compensate emotional problems due to selective targeting may explain why AAV-
APPs treatment effects were only seen during probe trial and reversal learning. Although 
hippocampal lesions have been demonstrated to impair hippocampus dependent behaviour 
(Morris et al, 1982), learning and memory also involves other brain regions that were not 
targeted by the injections including the dorsomedial striatum – prefrontal cortex network 
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which is strongly involved in the initial acquisition of the place-navigation task (Woolley et al, 
2013). The entorhinal cortex constitutes a crucial interface between the hippocampus and 
the rest of the cortex and is the source of most spatial information that is processed in the 
hippocampus (Hales et al, 2014; Vorhees & Williams, 2014). The fact that AAV-APPsα 
expression was largely restricted to the hippocampus may thus underlie the partial but not 
complete rescue of performance by APPsα in the MWM. In addition, part of the behavioural 
deficits may also be due to developmental effects of the mutation. 
 
Consistent with an important function of APPsα in the mature brain, acute depletion of 
APPsα in wild type animals by either pharmacological inhibition of α-secretase (Taylor et al, 
2008), or infusion of antibodies directed against the C-terminus of APPsα (Puzzo et al, 2011; 
Taylor et al, 2008) was reported to impair LTP and cognitive behaviour. However, these 
previous approaches lacked specificity, as secretase inhibitors target also other substrates 
besides APP and antibodies employed bind not only to APPsα, but also full length APP and 
A. Collectively, our findings indicate an important synaptotrophic role of APPsα in the 
mature CNS for spine density, synaptic plasticity and behaviour. Importantly, this role in 
cDKO mice (lacking endogenous APP and all its fragments including A) is completely 
independent of any indirect Aβ related effects, in contrast to the previously reported A 
lowering properties of APPsα in transgenic APP/PS1 mice (Fol et al, 2016; Obregon et al, 
2012). 
 
As APPsα and APPs are identical in primary sequence except for the last 16 amino acids 
one may expect that they should exhibit largely overlapping functions. Accordingly, only few 
studies have so far directly compared the effects mediated by either APPsα or APPs. In 
vitro, recombinant APPs was shown to more efficiently induce the differentiation of human 
embryonic stem cells into neuronal precursor cells as compared to APPsα (Freude et al, 
2011), whereas a similar increase in axonal outgrowth was observed when cortical neurons 
were treated with recombinant APPs or APPsα (Chasseigneaux et al, 2011). With regard to 
in vitro assays of neuroprotection, however, APPs was considerably less potent to protect 
neurons against glucose deprivation, excitotoxicity, A peptide (Barger & Harmon, 1997; 
Furukawa et al, 1996) or epoxomycin induced proteasomal stress (Copanaki et al, 2010). 
Here, we compared the in vivo functions of the secreted APP ectodomains in the adult brain. 
A surprising key finding was that APPsα and APPs exert strikingly different effects in vivo, 
despite a similar level and pattern of AAV mediated expression (Figure 1, 5C-E, EV1 and 
EV2). Of note, the absence of beneficial effects by AAV-APPs cannot be simply explained 
by possible adverse effects associated with AAV-APPs expression, as we found no signs of 
increased cell death, nor any evidence for increased astrogliosis or microgliosis (see 
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Appendix Figure S1) as unspecific signs of neurodegeneration. Although earlier studies had 
indicated that a fragment (N-APPs1-286) derived for APPs may induce caspase activation 
and death of sensory neurons in a mechanism requiring DR6 (Nikolaev et al, 2009), these 
data have recently been revised to exclude a requirement for -secretase activity and thus 
APPs (Olsen et al, 2014). Our notion that AAV-APPs does not induce adverse effects is 
further in agreement with previous data from fully viable and apparently normal APPs-
knockin (KI) mice expressing solely APPs (Li et al, 2010). However, whether a lack of 
APPsα in APPs-KI mice might lead to synaptic deficits, had remained unknown.  
 
We demonstrate that APPsα but not APPs rescues spine density and synaptic plasticity in 
cDKO mice and identified the CTα16 peptide of APPsα as a crucial LTP-enhancing functional 
domain that stimulated LTP to the same extent as recAPPsα. Mechanistically, facilitation of 
LTP by APPsα or the CTα16 peptide required functional α7-nAChRs since BTX, a selective 
antagonist of α7-nAChRs, blocked its effects. Moreover, when expressed in oocytes α7-
nAChRs could be directly potentiated by nanomolar amounts of either recAPPsα (but not 
recAPPs) or CTα16 in the presence of ACh or nicotine. Together with the ability of APPsα 
to enhance the sensitivity of α7-nAChRs for the agonist nicotine these data establish APPsα 
as a potent positive allosteric modulator (PAM). These findings also suggests that APPsα 
might function as an endogenous PAM of cholinergic signalling in the hippocampus, although 
further studies are required to confirm its activity in vivo. Several studies have shown that 
nAChR activation facilitates LTP induction (for review see Yakel, 2014) and α7-nAChRs are 
abundantly expressed in the hippocampus (Fabian-Fine et al, 2001). Several mechanisms of 
α7-nAChR signalling are thought to contribute to its role in LTP: (1) activation of presynaptic 
α7-nAChR can increase glutamate release and (2) activation of postsynaptic α7-nAChRs that 
have a high Ca2+ permeability may confer membrane depolarisation and induce plasticity 
evoking Ca2+ signalling (reviewed by McKay et al, 2007; Yakel, 2014). 
 
Although more work is needed to understand precisely how APPsα affects α7-nAChR 
signalling, we hypothesize that both pre- and postsynaptic mechanisms are likely to play a 
role. When applied to slices of cDKO mice both APPsα and CTα16 enhanced, in a BTX 
sensitive manner, the early phase of post tetanic potentiation (PTP) during the first minutes 
after start of baseline recording, which is believed to involve Ca2+ build up in presynaptic 
terminals. In line with an important endogenous role of APPsα for LTP, APPsα secretion is 
activity dependent (Fazeli et al, 1994; Gakhar-Koppole et al, 2008; Hoey et al, 2009; Mills & 
Reiner, 1999) and can thus be increased through plasticity-inducing protocols. The 
enhancement of PTP by APPsα, as observed in our study, is consistent with previous studies 
that reported increased Ca2+ influx in synaptoneurosomes and α7-nAChRs transfected 
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neuroblastoma cells upon application of low (picomolar) amounts of A or N-terminal A-
peptides that are overlapping with the C-terminus of APPsα (Dougherty et al, 2003; 
Lawrence et al, 2014). Recently, low (picomolar) amounts of A were shown to increase 
synaptic vesicle recycling via α7-nAChRs signalling in hippocampal neurons (Lazarevic et al, 
2017). Moreover, low amounts of A had been found to stimulate synaptic plasticity and 
memory in wildtype mice (Lawrence et al, 2014; Puzzo et al, 2011). In addition to presynaptic 
effects it is likely that APPsα will also modulate signalling at the postsynaptic site (for a 
review see Ludewig & Korte, 2016). Postsynaptic membrane depolarization due to Ca2+ 
influx through α7-nAChRs may increase the probability of NMDAR-activation that is crucial to 
induce stable LTP. In this regard, NMDAR inhibition has been shown to prevent the nicotine 
induced conversion of short term plasticity into LTP at CA3/CA1 synapses (Ji et al, 2001). 
Moreover, also activation of septal cholinergic input to induce α7-nAChRs dependent LTP 
required the activation of NMDARs (Gu & Yakel, 2011). In addition to signalling via α7-
nAChRs, APPsα may also modulate NMDARs more directly, as APPsα was shown to 
potentiate tetanically evoked NMDAR currents recorded at granule cells of the dentate gyrus 
in rat brain slices (Taylor et al, 2008) and full length APP can biochemically interact with 
GluN1/GluN2 receptors (Cousins et al, 2009), although it is not known whether this also 
holds true for APPsα. 
Our finding of distinct in vivo functions of APPsα and APPs have important implications for 
AD therapy. Pharmacological BACE1 inhibition has been a major approach to reduce A in 
animals and clinical trials. More recently, however, concerns have been raised that 
therapeutic BACE1 inhibition may also compromise important physiological functions of 
BACE (Yan & Vassar, 2014). Indeed, BACE-KO mice display deficits in synaptic morphology 
and synaptic plasticity in the hippocampus (Dominguez et al, 2005; Laird et al, 2005). Our 
data indicate that APPs deficiency that will result from BACE1 inhibition is unlikely to lead to 
toxic effects. A number of recent studies demonstrated that very low concentrations of A 
may stimulate transmitter release and modulate synaptic plasticity and memory. Strikingly, 
we now show that it is the C-terminal domain of APPsα that is required to increase spine 
density, rescues LTP and improves memory. As this C-terminal domain is also present in A 
it is conceivable that signaling of APPsα and soluble, non-aggregated A species may at 
least in part converge e.g. regarding the activation of α7-nAChRs. From this, one may 
speculate that APPsα may be able to rescue potential unwanted effects due to limited A 
levels. It is also clear however, that sequence context and structural accessibility of the 
CTα16 domain is crucial. Indeed, the presence of the CTα16 domain appears to alter the 
conformation of APPsα in a critical way. Analysis by small angle X-ray diffraction indicated 
that the 3D structure of APPsα and APPs are quite different, with APPsα exhibiting an 
extended conformation with an exposed CTα16 region (Gralle et al, 2006; Peters-Libeu et al, 
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2015) while in APPs the E1 domain folds back towards the C-terminal juxtamembrane 
region (Peters-Libeu et al, 2015). Thus, different 3D structures may enable or prevent 
binding to receptors, which may contribute to the distinct in vivo functions of APPsα and 
APPs. 
 
Regarding AD pathogenesis our data indicate that a shift towards -secretase processing 
that may occur during AD (Ahmed et al, 2010; Holsinger et al, 2002) could result in 
insufficient amounts of APPsα that cannot be functionally compensated by APPs. A lack or 
reduction of APPsα might thus contribute to deficits in synaptic plasticity and cognitive 
function in AD patients. Consistent with this notion, in AD patients hippocampal levels of 
synaptically localized ADAM10/SAP97 complexes are reduced (Epis et al, 2010) and an 
activity attenuating mutation in the human ADAM10 gene leading to reduced APPsα levels 
has been associated with AD (Kim et al, 2009; Suh et al, 2013). In familial AD cases carrying 
the Swedish mutation (APPSWE), cerebrospinal fluid (CSF) levels of APPsα were found to be 
reduced already at early stages of AD (Almkvist et al, 1997; Lannfelt et al, 1995). With regard 
to sporadic AD cases, however, no consensus has been reached whether reduced APPsα 
levels are associated with AD (Mockett et al, 2017). Early on, total soluble APPs was 
reported to be severely reduced in sporadic AD (Van Nostrand et al, 1992). Several more 
recent studies specifically detecting APPsα reported reduced APPsα levels in mild (Sennvik 
et al, 2000) to moderate AD (Rosen et al, 2012), or in APOE4 positive AD patients (Olsson et 
al, 2003), while several other studies found no difference in APPsα at early stages of 
sporadic AD (Brinkmalm et al, 2013; Perneczky et al, 2013; Perneczky et al, 2011; Rosen et 
al, 2012). These mixed results may in part be related to different assays systems used and 
the recent finding of considerable diurnal variability of APPsα and other APP fragments in the 
CSF (Dobrowolska et al, 2014). Thus, more detailed studies are needed to resolve these 
important issues.  
 
In preclinical AD research, numerous studies have been conducted using APP transgenic 
mouse models (https://www.alzforum.org/research-models) which (over)express huAPPSWE 
that undergoes enhanced -secretase processing. Consequently, reduced levels of 
neuroprotective and synaptotrophic APPsα relative to increased amounts of A (that is a 
reduced APPsα/A ratio) may fail to adequately balance and antagonize the detrimental 
effects of A and thus contribute to the phenotypic and synaptic impairments in these 
transgenic mice. 
 
APPsα also plays an important role in processes of natural aging. Not only is memory 
performance correlated with APPsα levels in rats (Anderson et al, 1999), but also aging-
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related deficits in LTP and cognitive behaviour can be rescued by exogenous APPsα 
(Moreno et al, 2015; Xiong et al, 2016). Collectively, our findings indicate distinct functions 
for APPsα in the adult brain to modulate spine density, synaptic plasticity and cognition. Our 
findings lend further support to therapeutic approaches aimed at directly or indirectly 
increasing APPsα expression in the brain (Mocket et al., 2017, Müller et al, 2017) to 
ameliorate synaptic deficits in AD or possibly also for other diseases in which neurons are 
damaged.  
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Figure Legends 
 
Figure 1: Expression of APPsα in the hippocampus of AAV-APPsα injected 
cDKO animals. A Schematic representation of monocistronic and bicistronic AAV 
constructs enabling neuron-specific expression of i) Venus and ii) HA-tagged APPsα 
(+ Venus). ITR: inverted terminal repeat, Synapsin: promotor, T2A: Thoseaasigna 
virus 2A site, SP: signal peptide, HA: influenza hemagglutinin tag. B Scheme of the 
hippocampus with coordinates of the two injection sites (black stars). C Overview of 
the hippocampus of an AAV-APPsα injected cDKO mouse. HA-tag staining (red) 
reveals APPsα expression within the CA1, CA3 and DG of the hippocampus.  
Magnification shows the boxed CA1 region. Scale bars: 500 μm (left), 100 µm (right). 
DG: Dentate Gyrus, CA: Cornus Ammonis. D-G Double immunostaining in CA1 
region. APPsα (HA-tag, red) is exclusively expressed in neurons (NeuN, blue, D, E), 
but not in astrocytes (GFAP, blue, F) or microglia (Iba1, blue, G). Scale bars: 10 μm 
(D, F, G), 5 µm (E). H Western blot analysis of APP expression in hippocampus of 
LM control (N=5) and cDKO mice (N=5) injected with AAV-Venus or AAV-APPsα. 
Age of mice: 5-6 months.  
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Figure 2: AAV-APPsα rescues LTP, impaired short-term synaptic plasticity and 
spine density of cDKO mice. A, B LTP was induced at hippocampal CA3-CA1 
synapses after 20 min baseline recordings (arrowhead, TBS). cDKO mice expressing 
Venus (red) exhibited significant lower induction and maintenance of LTP (128.12 ± 
3.41%) compared to Venus injected LM controls (white, 156.69 ± 4.75%, ###p<0.001). 
AAV mediated expression of APPsα (green) restored potentiation after start of 
baseline recording and resulted in an LTP curve comparable to that of LM controls. 
The LTP induction rate is shown as percentage % of mean baseline slope. Data 
points were averaged over 6 time points. C The deficit of PPF in Venus injected 
cDKO mice at the 10 ms (#p<0.05) and 20 ms (#p<0.05) ISI was restored by 
expression of APPsα. n=number of slices. N=number of animals. D Representative 
images of basal and midapical dendritic segments of CA1 neurons. E, F The spine 
density deficit of Venus injected cDKOs mice (11% in basal and 18% in midapical 
dendrites) is rescued by APPsα to LM control levels. Images are maximum 
projections of deconvolved z-stacks. Scale bar: 5 µm. Spine density was normalized 
to LM control levels. n=number of neurons (from 5 animals per condition). A-F Age of 
mice at analysis: 5-6 months. Data represent mean ± SEM. Data were analyzed by 
one-way ANOVA followed by Bonferroni´s post-hoc test. # indicates significant 
differences between LM control and cDKO injected with AAV-Venus, * between 
cDKO injected with AAV-Venus or APPsα. nsp>0.05, */#p<0.05, **/##p<0.01, 
***/###p<0.001. 
 
Figure 3: APPsα ameliorates dendritic branching abnormalities of cDKO 
animals 
A Representative 3D-reconstructions of CA1 pyramidal neurons from AAV-Venus 
injected LM controls (left), AAV-Venus injected cDKOs (middle, red) and AAV-APPsα 
injected cDKOs (right, green). B Schematic representation of parameters assessed. 
C-F Compared to LM controls AAV-Venus injected cDKO mice show a significantly 
reduced basal (##p<0.01, C) and apical (##p<0.01, E) dendritic length and reduced 
branching in basal (##p<0.01, D) and apical (##p<0.01, F) dendrites. AAV-APPsα 
injection did neither affect basal (nsp>0.05, C) nor apical (nsp>0.05, E) total dendritic 
length. However, the total number of basal nodes differed significantly compared to 
AAV-Venus injected cDKO mice (*p<0.05, D). G Sholl analysis of basal dendritic 
length reveals a significant group effect (repeated measures ANOVA: genotype F(2, 
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29)=5.038, p<0.05) and a significant distance effect (repeated measures ANOVA: 
genotype F(5, 145)=250.2, p<0.0001). Due to a significant interaction effect 
(repeated measures ANOVA: genotype F(10, 145)=4.466, p<0.0001), a post-hoc 
Sidak’s multiple comparison test was performed to further evaluate effects between 
groups at distinct distances from soma. Compared to Venus injection, AAV-APPsα 
injection of cDKO significantly increased basal dendritic length at 60 µm (*p<0.05). H 
Sholl analysis of apical dendritic length reveals an overall significant group effect 
(repeated measures ANOVA: genotype F(2, 37)=4.776, p<0.05) and a significant 
distance effect (repeated measures ANOVA: genotype F(18, 666)=47.54, p<0.0001). 
Due to a significant interaction effect (repeated measures ANOVA: genotype F(36, 
666)=1.640, p<0.05), a post-hoc Sidak’s multiple comparison test was performed to 
further evaluate effects between groups at distinct distances from soma. AAV-APPsα 
expression increased midapical dendritic length at 300 µm (**p<0.01) and 330 µm 
(**p<0.01) distance from soma compared to AAV-Venus injected cDKO mice. A-H 
Age of mice: 5-6 months. n=number of neurons (from 4-5 animals per condition). 
Data represent mean ± SEM. Data were analyzed by one-way ANOVA followed by 
Bonferroni´s post-hoc test (C-F) or repeated measures ANOVA followed by 
Bonferroni´s or Sidak’s post-hoc test (G-H). # indicates significant differences 
between LM control and cDKO injected with AVV-Venus, * between cDKO injected 
with AAV-Venus or APPsα, ● between LM control injected with Venus and cDKO 
injected with AAV-APPsα. nsp>0.05, */#/●p<0.05, **/##/●●p<0.01, ***/###/●●●p<0.001. 
 
Figure 4: APPsα improves place navigation and spatial memory of cDKO mice 
in the MWM A Swim speed during acquisition and reversal learning is comparable in 
all groups (each point represents one day with 6 trials). B During acquisition learning 
and after platform reversal to the opposite quadrant, AAV-Venus injected cDKOs (red 
circles) show considerably longer escape latency compared to AAV-Venus injected 
LM controls (white circles). AAV-APPsα injected cDKO mice (green circles) show an 
overall intermediate performance (genotype F(2, 46)=6.361, p=0.0036) and that 
differs significantly at day 5 of reversal learning compared to AAV-Venus injected 
cDKO mice (genotype x day F(8,184)=5.266, p<0.0001; **p<0.01). C Measurements 
of swim path length confirms the training performance deficit of cDKO mice 
compared to LM controls. During the reversal phase, the performance of AAV-APPsα 
injected cDKOs is significantly improved at day 5 (genotype F(2,46)=16.70, 
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p<0.0001, genotype x day F(8,184)=5.788, p<0.0001; *p<0.05, ●●p<0.01). D In the 
probe trial, AAV-Venus injected cDKOs (red) spend significantly less time in the 
target zone compared to AAV-Venus (###p<0.001) injected LM control animals (white) 
and failed to prefer it significantly over control zones in adjacent quadrants. Note that 
expression of APPsα (green) largely rescues the deficits of cDKOs. N=22 (LM 
controls: AAV-Venus), N=18 (cDKOs: AAV-Venus), N=18 (cDKOs: AAV-APPsα). 
Data represent mean ± SEM. Dashed lines: chance level. Data were analyzed using 
a mixed ANOVA model with conditions (LM control: AAV-Venus, cDKO: AAV-Venus 
and cDKO: AAV-APPsα) as between subject factor. Within subject factors were 
added to explore the dependence of genotype effects on day and place. Significant 
interactions and main effects were further explored by pairwise FDR-corrected two-
tailed Student’s t-tests. # indicates significant differences between LM control and 
cDKO injected with AVV-Venus, * between cDKO injected with AAV-Venus or 
APPsα, ● between LM control injected with Venus and cDKO injected with AAV-
APPsα nsp>0.05, */#/●p<0.05, **/##/●●p<0.01, ***/###/●●●p<0.001. 
 
Figure 5: AAV-APPsβ fails to rescue LTP or spine density in vivo, while CTα16  
facilitates LTP in vitro. A Schematic representation of AAV9 constructs enabling the 
neuron-specific expression of i) Venus and ii) HA-tagged APPsβ (+ Venus). ITR: 
inverted terminal repeat, Synapsin: neuron specific promotor, T2A: Thoseaasigna 
virus 2A site, SP: signal peptide, HA: influenza hemagglutinin tag. B APPsα differs 
from APPsβ in the last 16 C-terminal amino acids (CTα16, green). The epitope 
recognized by the M3.2 antibody is indicated. C Overview of the hippocampus of a 
AAV-APPsβ (HA-tag, red) injected cDKO mouse. APPsβ is expressed in CA1, CA3 
and DG. Scale bar: 500 μm. DG: dentate gyrus, CA: Cornus Ammonis. D Western 
blot analysis of HA-APPsα and HA-APPsβ in hippocampi of injected mice (boxed 
upper panel), probed with an HA-tag specific antibody (lower band, arrowhead; 
*unspecific signal). Homogenates of AAV injected hippocampi were subjected to 
ultracentrifigation to detect soluble APPs and APPs (UC supernatant; boxed lower 
panel). The APP C-terminal antibody Y188 was used to confirm the separation of 
soluble APPsα from membrane bound full-length APP that is detected in total lysates 
of AAV-Venus injected littermate controls. Hippocampi of APP-/- mice served as a 
negative control for antibody specificity. E Quantification of HA-APPsα and HA-
APPsβ expression in total hippocampal homogenates and of soluble HA-APPs after 
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UC normalized to β-tubulin. Note the comparable expression in AAV-APPsα and 
AAV-APPsβ injected mice. Age: 5-6 months. N=Number of animals. Data represent 
mean ± SEM. Data were analyzed by unpaired two-tailed Student’s t test. nsp>0.05. 
F-H Activity dependent synaptic plasticity was investigated in cDKO after injection of 
AAV-Venus (red) or APPsβ (blue). F, G AAV-mediated overexpression of APPsß 
(n=23 slices, blue symbols) failed to rescue the LTP defect of cDKO mice (n=24 
slices, red symbols). G TBS induced strengthening of fEPSPs resulted in similar 
potentiation levels for the last 5 minutes of recording (t75-80). The LTP induction rate 
is shown as percentage % of mean baseline slope. Data points were averaged over 
6 time points. H PPF paradigm yielded no significant differences between viral vector 
injected cDKO mice. Age: 5-6 months. n=number of recorded slices. N=number of 
animals. Data represent mean ± SEM. Data were analyzed unpaired two-tailed 
Students t-test. I Representative images of Golgi stained midapical and basal 
dendritic segments of LM control and cDKO animals injected with AAV-Venus or 
AAV-APPsβ. J, K The significant spine density deficit of AAV-Venus injected cDKO 
mice (red bar) in basal (J) and apical dendrites (K) was comparable and not 
significantly different (nsp>0.05) from that of AAV-APPsβ injected cDKO mice (blue 
bar). White bar: AVV-Venus injected LM controls. Images are maximum projections 
of z-stacks. Scale bar: 5 µm. Spine density is normalized to LM control levels. Age: 5-
6 months; n=number of neurons (from 5 animals per condition). Data represent mean 
± SEM. Data were analyzed by one-way ANOVA followed by Bonferroni´s post-hoc 
test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 . L, M Acute hippocampal slices of 
cDKO were pre-incubated for 1 hour either with 10 nM CTα16 or CTα16scr before 
inducing LTP by TBS (arrowhead). Averaged potentiation levels at LTP induction 
(t20-25) revealed a significantly enhancement by CTα16 as compared to CTα16scr 
present over the whole recoding time. Potentiation levels at t75-80 are significantly 
increased in the presence of CTα16 (**p<0.01). The LTP induction rate is shown as 
percentage % of mean baseline slope. Data points were averaged over 6 time points. 
N CTα16 significantly enhances short-term synaptic plasticity at inter-stimulus 
intervals of 40 (**p<0.01), 80 (*p<0.05), and 160 (**p<0.01) ms compared to 
CTα16scr. O-Q Acute application of CTα16 and recAPPsα elevates LTP in cDKO 
slices to the same extent. O, P After 1 hour pre-incubation with either 10 nM CTα16 
or 10 nM recAPPsα fEPSPs were recorded. The TBS induced LTP curve was closely 
overlapping for both conditions and resulted in similar, statistically not significantly 
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different LTP values Q CTα16 and recAPPsα modulate presynaptic function of cDKO 
mice in the same manner. Age: 5-6 months. n=number of recorded slices. N=number 
of animals. Data represent mean ± SEM. Data were analyzed by unpaired two-tailed 
Students t-test. 
 
Figure 6: LTP facilitation by APPs or CTα16 requires functional α7-nAChRs 
A, B Treatment with 10 nM α-BTX (30 min prior to TBS, black circles) significantly 
reduces LTP induction (t20-25, phase of post tetanic potentiation) and maintenance 
(t75-80) in LM controls expressing endogenous APP and APPsα. The LTP induction 
rate is shown as percentage % of mean baseline slope. Data points were averaged 
over 6 time points. C Experimental set-up: co-application of recAPPsα or CTα16 and 
BTX before LTP induction. Peptides and BTX inhibitor used for pre-incubation 
circulated throughout the whole LTP recording. D, E Co-application of BTX and 
recAPPsα significantly inhibits synaptic plasticity in cDKO mice. After 1 hour pre-
incubation of acute slices with 10 nM recAPPsα or 10 nM recAPPsα and 10 nM BTX 
fEPSPs were recorded. Hippocampal acute slices treated with 10 nM BTX and 
recAPPsα revealed significantly impaired induction (t20-25) and maintenance (t75-
80) of LTP in comparison to slices of cDKO mice recorded in the presence of 
recAPPsα alone. F, G Co-application of BTX and CTα16, the C-terminal domain of 
APPsα, significantly inhibits synaptic plasticity in cDKO mice. After 1 hour pre-
incubation of acute slices with 10 nM CTα16, or 10 nM CTα16 and 10 nM BTX 
fEPSPs were recorded. Hippocampal acute slices treated with 10 nM BTX and 
CTα16 revealed similar to recAPPsα, a significantly impaired induction (t20-25) and 
maintenance (t75-80) of LTP in comparison to slices of cDKO mice recorded in the 
presence of CTα16 alone. Age: 5-6 months of age. n=number of recorded slices. 
N=number of animals. Data represent mean ± SEM. Data were analysed by unpaired 
two-tailed Students t-test. *p<0.05, **p<0.01. 
 
Figure 7: Potentiating effect of CT16 and APPs on recombinant homomeric 
7-nAChRs. A Nicotine- and acetylcholine-induced whole-cell current traces of 7-
nAChRs expressed in Xenopus oocytes recorded in the absence or presence of 
CT16 or CT16scr, respectively. Note specific robust potentiation of nicotine- and 
acetylcholine-induced currents by CT16, but no direct activation of 7-nAChRs by 
either peptide in the absence of agonist (not shown). Bars indicate application of 
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EC50 agonist concentrations and of the peptide indicated (green: CT16: grey: 
CT16scr). B Quantification of potentiation shows that CT16 enhances nicotine- and 
acetylcholine-induced currents to a similar extend whereas CT16scr had no effect. C 
CT16 dose-response curve obtained with submaximal nicotine concentrations 
(100 µM) with a corresponding EC50 value of 10.7 ± 4.6 nM and a hill-coefficient of 
2.1 ± 0.3 (n=4). D Nicotine-induced whole-cell current traces of 7-nAChRs in the 
presence of 20 nM recAPPs (green bar) or 20 nM recAPPs (blue bar). Note that 
only recAPPs efficiently potentiates7-nAChRs, which is blocked by BTX (orange 
bar). E Quantification of potentiation shows that recAPPs enhances nicotine-
induced currents to a similar extend as CT16 (see for comparison Figure 7B) while 
recAPPs had no effect. F Nicotine dose-response curve obtained either in the 
presence of 20 nM recAPPs (green circles, left) or without treatment (black circles, 
right). Note that recAPPs treatment shifts the curve to the left, significantly reducing 
the apparent agonist affinity by about 2-fold (EC50 of 40.3 ± 6.0 µM, green curve vs. 
EC50 of 80.5 ± 12.7 µM, black curve; n=5; *p<0.05). For statistical evaluation of 
potentiation we performed a paired two-tailed Students t-test of the agonist-induced 
currents in the absence and presence of the indicated peptide. n=number of oocytes. 
Data represent mean ± SEM. nsp>0.05, *p<0.05. 
 
 
 
 
Expanded View Legends 
 
EV1: AVV-Venus and  AVV-APPs vectors mediate comparable neuron specific 
expression throughout the dorsal hippocampus. A Double immunostaining of 
CA1 pyramidal cells. APPsβ (HA-tag, red) is exclusively expressed in neurons 
(NeuN, blue, left), but not in astrocytes (GFAP, blue, middle) or microglia (Iba1, blue, 
right). Scale bar: 20 μm. B Expression was investigated by immunohistochemistry in 
different coronal sections from dorsal to ventral. C Venus, APPsα and APPsβ (HA-
tag) expression is shown for different sections of the hippocampus. Expression is 
absent in ventral portions of the hippocampus. Scale bar: 1 mm.  
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Figure EV2: APPsα and APPsβ are transported through the secretory pathway 
and secreted efficiently. A Western blot analysis of lysate (L) and supernatant (SN) 
of pAAV-APPsα and pAAV-APPsα transfected HEK293T cells using an HA-tag 
specific antibody. Note the secretion of HA-APPsα and HA-APPsβ into the cell 
supernatant. Mature APPs is posttranslationally modified and runs at slightly higher 
MW. B Western blot analysis of medium from cortical neurons transduced with AAV-
APPsα or AAV-APPsβ. 105 cDKO neurons were transduced at DIV7 with 104 
genome copies per cell of either AAV-APPsα or AAV-APPsα. After 12 days medium 
was exchanged and neuronal supernatants were harvested on the next day. Equal 
amounts (2 µl) of supernatant were subjected to capillary electrophoresis followed by 
immunodetection (WES system, ProteinSimple, USA). Note that similar amounts of of 
HA-APPsα and HA-APPsβ are secreted into the medium of transduced neurons. C-E 
Immunocytochemistry of neurons transduced with AAV-APPsα or AAV-APPsβ 
neurons. Transduced neurons positive for the neuronal marker NeuN (red) were 
identified by Venus expression (green). D, E Confocal images of neurons stained 
with the ER marker Calreticulin (green), the Golgi marker Giantin (green)  and α-HA 
staining to detect APPs (red). Note that both HA-APPsα and HA-APPsβ show co-
localization (white arrows) with  the ER (D) and Golgi markers (E) indicating 
successful transport through the secretory pathway. Scale bars: 100 μm (C), 10 µm 
(D,E). 
 
EV3: Basal transmission in cDKO mice treated with APPsα or APPsβ is not 
altered compared to LM control animals injected with Venus.  
A, C Neuronal excitability is comparable at all stimulus intensities (25-250 µA) 
between all groups injected with the indicated AAV vectors. B, D No significant  
alterations can be detected when analyzing the Input-Output (IO) strength of the viral 
vector injected groups of mice at any fiber volley (FV) amplitude. 
 
EV4: Inhibition of 7-nAChRs by BTX after APPs pre-incubation does not 
inhibit LTP A Experimental set-up: pre-application of APPsα or CTα16 before 
addition of 10 mM Bungarotoxin (BTX) 30 min prior to TBS (arrowhead). B, C  
Hippocampal acute slices treated with APPsα for 1 h and subsequent addition of 10 
nM BTX did not significantly impair induction (t20-25) and maintenance of LTP (t75-
80) in comparison to slices of cDKO mice recorded in the presence of APPsα alone. 
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D, E The treatment with CTα16 for 1 h and subsequent addition of 10 nM BTX did not 
significantly impair induction (t20-25) or maintenance of LTP (t75-80). Age: 5-6 
months of age. n=number of recorded slices, N=number of animals. Data represent 
mean ± SEM. Data were analysed by unpaired two-tailed Students t-test. nsp>0.05. 
 
EV5: Neither CTα16 nor APPsα potentiate the homomeric α1 glycine receptor. 
A Glycine-induced whole-cell current traces of homomeric α1 glycine receptor (GlyR) 
expressed in Xenopus oocytes recorded in the absence or presence of CTα16 or 
APPsα, respectively. No direct activation of α1-GlyR by CTα16 or APPsα in the 
presence of the agonist was detected (not shown). Bars indicate application of EC50 
glycine concentrations and of the peptide indicated. B Quantification of potentiation 
shows that neither CTα16 nor APPsα effect glycine-induced currents. Data represent 
mean ± SEM. Data were analysed by paired two-tailed Students t-test. nsp>0.05. 
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